RU2005127667A - Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза - Google Patents
Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза Download PDFInfo
- Publication number
- RU2005127667A RU2005127667A RU2005127667/15A RU2005127667A RU2005127667A RU 2005127667 A RU2005127667 A RU 2005127667A RU 2005127667/15 A RU2005127667/15 A RU 2005127667/15A RU 2005127667 A RU2005127667 A RU 2005127667A RU 2005127667 A RU2005127667 A RU 2005127667A
- Authority
- RU
- Russia
- Prior art keywords
- progestin
- estrogen
- aromatase inhibitor
- combination
- endometriosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Применение комбинации ингибитора ароматазы, прогестина и эстрогена для приготовления лекарственного средства для лечения эндометриоза.
2. Применение в соответствии с п.1, где ингибитор ароматазы выбран из атаместана, форместана, фадрозола, летрозола, пентрозола, анастрозола и ворозола.
3. Применение в соответствии с п.2, где ингибитор ароматазы представляет собой анастрозол.
4. Применение в соответствии с п.1, или 2, или 3, где прогестин выбран из норгестрела, левоноргестрела, норэтиндрона, ацетата норэтиндрона, дезогестрела, норгестимата и диацетата этинодиола.
5. Применение в соответствии с п.4, где прогестин представляет собой левогестрол.
6. Применение в соответствии с п.1, или 2, или 3, где эстроген выбран из этинилэстрадиола и местранола.
7. Применение в соответствии с п.6, где эстроген представляет собой этинилэстрадиол.
8. Применение по п.1, где ингибитор ароматазы представляет собой анастрозол, прогестин представляет собой левоногестрол, а эстроген представляет собой этинилэстрадиол.
9. Фармацевтическая композиция, содержащая комбинацию в соответствии с любым из пп.1-8.
10. Фармацевтическая композиция в соответствии с п.9 для лечения эндометриоза.
11. Способ лечения эндометриоза, который включает введение комбинации ингибитора ароматазы, прогестина и эстрогена.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0302572.3 | 2003-02-05 | ||
| GBGB0302572.3A GB0302572D0 (en) | 2003-02-05 | 2003-02-05 | Method of treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008138166/15A Division RU2008138166A (ru) | 2003-02-05 | 2008-09-25 | Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005127667A true RU2005127667A (ru) | 2006-03-27 |
| RU2360681C2 RU2360681C2 (ru) | 2009-07-10 |
Family
ID=9952433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005127667/15A RU2360681C2 (ru) | 2003-02-05 | 2004-02-03 | Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза |
| RU2008138166/15A RU2008138166A (ru) | 2003-02-05 | 2008-09-25 | Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008138166/15A RU2008138166A (ru) | 2003-02-05 | 2008-09-25 | Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7910570B2 (ru) |
| EP (2) | EP1857111A3 (ru) |
| JP (2) | JP4658918B2 (ru) |
| KR (1) | KR101075929B1 (ru) |
| CN (1) | CN100393360C (ru) |
| AR (1) | AR043013A1 (ru) |
| AT (1) | ATE374612T1 (ru) |
| AU (1) | AU2004210184B2 (ru) |
| BR (1) | BRPI0407039A (ru) |
| CA (1) | CA2513910C (ru) |
| CO (1) | CO5580789A2 (ru) |
| CY (1) | CY1107816T1 (ru) |
| DE (1) | DE602004009288T2 (ru) |
| DK (1) | DK1589976T3 (ru) |
| ES (1) | ES2293215T3 (ru) |
| GB (1) | GB0302572D0 (ru) |
| HK (1) | HK1082918A1 (ru) |
| IL (1) | IL169583A0 (ru) |
| IS (1) | IS2547B (ru) |
| MX (1) | MXPA05008347A (ru) |
| MY (1) | MY140723A (ru) |
| NO (1) | NO20053626L (ru) |
| NZ (1) | NZ541222A (ru) |
| PL (1) | PL214680B1 (ru) |
| PT (1) | PT1589976E (ru) |
| RU (2) | RU2360681C2 (ru) |
| TW (1) | TWI354556B (ru) |
| UA (1) | UA80741C2 (ru) |
| WO (1) | WO2004069260A1 (ru) |
| ZA (1) | ZA200506221B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
| MX2007003870A (es) * | 2004-10-04 | 2007-10-02 | Wayne State Unviersity | Uso de inhibidores de aromatasa para adelgazamiento endometrial en preparacion para procedimientos quirurgicos en la cavidad endometrial y utero. |
| WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
| DE102010003494A1 (de) * | 2010-03-31 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
| EP2476409A1 (en) * | 2011-01-14 | 2012-07-18 | Université Catholique De Louvain | Implant comprising a core and a tube encasing the core |
| RU2541089C1 (ru) * | 2013-11-22 | 2015-02-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук | Способ комплексного лечения наружного генитального эндометриоза |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| CN109248166A (zh) * | 2017-07-13 | 2019-01-22 | 国家卫生计生委科学技术研究所 | 阿那曲唑储库型阴道环的制备及应用 |
| KR20240076617A (ko) | 2022-11-22 | 2024-05-30 | 성균관대학교산학협력단 | 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8813353D0 (en) | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| DE69022722T2 (de) * | 1989-03-10 | 1996-05-02 | Endorecherche Inc., Ste-Foy, Quebec | Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen. |
| JP2602456B2 (ja) | 1990-04-12 | 1997-04-23 | 雪印乳業株式会社 | 子宮内膜症治療剤 |
| DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| US5681817A (en) | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| TR200100063T2 (tr) | 1998-06-11 | 2001-05-21 | Endorecherche, Inc | Androst-5-en-3ß,17ß-diol için farmasötik kompozisyonlar ve kullanımlar |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| US20040192598A1 (en) | 2000-10-11 | 2004-09-30 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| MXPA03006607A (es) | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
| AU2002240949A1 (en) | 2001-03-21 | 2002-10-03 | Schering Aktiengesellschaft | Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy |
| GB0120147D0 (en) | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
| WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
| IL161630A0 (en) | 2001-11-06 | 2004-09-27 | Applied Research Systems | Methods of treating endometreosis |
| KR20040073572A (ko) | 2002-01-22 | 2004-08-19 | 악조 노벨 엔.브이. | 내인성 에스트로겐의 합성을 예방하는 약물의 투여와관련된 호소 증상의 치료에서의 티볼론 |
| AU2003213958A1 (en) | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Female birth control method |
| AU2003213957A1 (en) | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| AU2003213956A1 (en) | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Improved hormone replacement therapy |
| US20040120956A1 (en) * | 2002-06-27 | 2004-06-24 | Song Xiao-Yu R. | CNGH0004 polypeptides, antibodies, compositions, methods and uses |
| GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
-
2003
- 2003-02-05 GB GBGB0302572.3A patent/GB0302572D0/en not_active Ceased
-
2004
- 2004-01-29 TW TW093101969A patent/TWI354556B/zh not_active IP Right Cessation
- 2004-02-03 EP EP07016253A patent/EP1857111A3/en not_active Withdrawn
- 2004-02-03 CN CNB2004800035630A patent/CN100393360C/zh not_active Expired - Fee Related
- 2004-02-03 BR BR0407039-9A patent/BRPI0407039A/pt not_active IP Right Cessation
- 2004-02-03 JP JP2006502229A patent/JP4658918B2/ja not_active Expired - Fee Related
- 2004-02-03 DE DE602004009288T patent/DE602004009288T2/de not_active Expired - Lifetime
- 2004-02-03 NZ NZ541222A patent/NZ541222A/en not_active IP Right Cessation
- 2004-02-03 KR KR1020057014375A patent/KR101075929B1/ko not_active IP Right Cessation
- 2004-02-03 RU RU2005127667/15A patent/RU2360681C2/ru not_active IP Right Cessation
- 2004-02-03 PL PL377939A patent/PL214680B1/pl unknown
- 2004-02-03 CA CA2513910A patent/CA2513910C/en not_active Expired - Fee Related
- 2004-02-03 WO PCT/GB2004/000414 patent/WO2004069260A1/en active IP Right Grant
- 2004-02-03 ES ES04707574T patent/ES2293215T3/es not_active Expired - Lifetime
- 2004-02-03 PT PT04707574T patent/PT1589976E/pt unknown
- 2004-02-03 EP EP04707574A patent/EP1589976B1/en not_active Expired - Lifetime
- 2004-02-03 DK DK04707574T patent/DK1589976T3/da active
- 2004-02-03 MX MXPA05008347A patent/MXPA05008347A/es active IP Right Grant
- 2004-02-03 AU AU2004210184A patent/AU2004210184B2/en not_active Ceased
- 2004-02-03 AR ARP040100329A patent/AR043013A1/es not_active Application Discontinuation
- 2004-02-03 US US10/543,584 patent/US7910570B2/en not_active Expired - Fee Related
- 2004-02-03 AT AT04707574T patent/ATE374612T1/de active
- 2004-02-04 MY MYPI20040307A patent/MY140723A/en unknown
- 2004-03-02 UA UAA200508473A patent/UA80741C2/uk unknown
-
2005
- 2005-07-07 IL IL169583A patent/IL169583A0/en not_active IP Right Cessation
- 2005-07-26 NO NO20053626A patent/NO20053626L/no not_active Application Discontinuation
- 2005-08-01 CO CO05075357A patent/CO5580789A2/es not_active Application Discontinuation
- 2005-08-03 ZA ZA200506221A patent/ZA200506221B/en unknown
- 2005-08-30 IS IS8008A patent/IS2547B/is unknown
-
2006
- 2006-03-06 HK HK06102877A patent/HK1082918A1/xx not_active IP Right Cessation
-
2007
- 2007-11-29 CY CY20071101527T patent/CY1107816T1/el unknown
-
2008
- 2008-09-25 RU RU2008138166/15A patent/RU2008138166A/ru not_active Application Discontinuation
-
2010
- 2010-09-20 US US12/886,269 patent/US20110009373A1/en not_active Abandoned
- 2010-10-07 JP JP2010227516A patent/JP2011001388A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008138166A (ru) | Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза | |
| EA200600964A1 (ru) | Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина | |
| Dammacco et al. | Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study | |
| RU2350327C2 (ru) | Составы, вызывающие потерю веса | |
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| RU96115196A (ru) | Состав для контрацепции | |
| RU96119957A (ru) | Фармацевтический комбинированный препарат для гормональной контрацепции | |
| RU2009120528A (ru) | Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла | |
| Chwalisz et al. | The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women | |
| DE60218881D1 (de) | Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen | |
| JP2009508808A5 (ru) | ||
| CA2420292A1 (en) | Contraception process and administration form for the same | |
| ES2348038T5 (es) | Preparado polifásico para la contracepción sobre la base de un estrógeno natural | |
| AR016502A1 (es) | Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas. | |
| JP2010539153A5 (ru) | ||
| Cedars | Triphasic oral contraceptives: review and comparison of various regimens | |
| US20050064031A1 (en) | Combination contraceptive, kits that contain the latter, and a method that uses the latter | |
| JP2013047269A (ja) | 経口避妊薬の形での機能不全子宮出血の経口治療のためへの吉草酸エストラジオール又はエストラジオールとジエノゲストとの使用 | |
| Brown-Grant | Failure of ovulation after administration of steroid hormones and hormone antagonists to female rats during the neonatal period | |
| EP1286666B1 (en) | Starter kit for low dose oral contraceptives | |
| RU2003112974A (ru) | Комбинированная терапия для лечения эстрогенчувствительных заболеваний | |
| Chetkowski et al. | Autonomous cortisol secretion by a lipoid cell tumor of the ovary | |
| JPH09500112A (ja) | ざ瘡治療用ホルモン剤及びその使用法 | |
| EA200200282A1 (ru) | Мезопрогестины (модуляторы рецептора прогестерона) в качестве средств лечения и предупреждения доброкачественных, зависящих от гормонов гинекологических нарушений | |
| RU1789216C (ru) | Состав, обладающий контрацептивным действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150204 |